Navigation Links
Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
Date:10/13/2008

ependent Data Safety Monitoring Board (DSMB) that will examine futility as well as safety. This constitutes a "go, no-go" decision point for the Viprinex clinical program. Passing the futility analysis would indicate that the drug has met predetermined interim efficacy criteria.

Because full enrollment of the consolidated trial is expected to be completed in the first quarter of 2009, NTI will not perform a superiority analysis during the interim review, in order to avoid taking a significant statistical penalty at the conclusion of the trial. Performing the interim futility analysis as planned does not carry any statistical penalty.

"We are very excited that after more than four years of hard work on our stroke program, we are rapidly approaching these two major milestones," stated Warren W. Wasiewski, M.D., vice president and chief medical officer. "Along with the rest of the stroke-care community, which has few treatment options at its disposal, I look forward with great enthusiasm to both the DSMB recommendation and the results of trial's final analysis."

Conference Call Details

NTI will hold a conference call to discuss this development later today at 1:00 p.m. (ET), 10:00 a.m. PT. The dial-in number is 877-440-5803 in the U.S. & Canada and 719-325-4942 elsewhere in the world. A telephonic replay will be available from 1:00 p.m. ET on October 13, 2008 to midnight ET on October 20, 2008. The replay number is 888-203-1112 in the U.S and Canada and 719-457-0820 elsewhere. The pass code is 9164451 for the conference calls.

About the Current Viprinex Stroke Trials

The ongoing Phase 3 clinical studies are designed to assess the efficacy and safety of Viprinex for the treatment of acute ischemic stroke when initiated within six hours of stroke onset. The studies are randomized, double-blind, placebo-controlled trials. Approximately 145 clinical sites are open to enroll patients into the trials in 14 countries.

About Neu
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
2. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
3. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
4. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
5. Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation
6. ImmunoVaccine Technologies DepoVax(TM) Shows Positive Results for Cancer and Infectious Diseases
7. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)
8. Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients
9. Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America
10. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
11. New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015   Leatt Corporation  (OTCQB: LEAT), a ... for all forms of sports, including extreme motor sports, ... announced today that the UISP Lega Motociclismo Lombardia, an ... riders to wear a neck brace during its racing ...
(Date:1/23/2015)... 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... development and sale of patented biopharmaceutical medicine, modernized traditional ... (API) today announced the business and development progress at ... 1. Following the September 2014 JCM application (No. 51268) ...
(Date:1/22/2015)... 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or ... Omega-3 therapies for cardiovascular disease and overall health is pleased ... in 2014 and its outlook for 2015 from the CEO, ... We would like to take this opportunity to ...
Breaking Medicine Technology:Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... , , , , ... , THE WOODLANDS, Texas, July 21 ... biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, ... for Orphan Medical Products (COMP) of the European Medicines Agency (EMEA) for ...
... , TOKYO, July 21 R-Tech Ueno, Ltd. ... on the new compound RK-023 that is being developed by our ... see the note below) has been completed. , ... of a patch test (open, closed, photo-patch test), single-dose study and ...
Cached Medicine Technology:Lexicon's Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA 2Lexicon's Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA 3Lexicon's Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA 4R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023 2R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023 3
(Date:1/22/2015)... Liberty University has received accreditation for its ... the Council for Accreditation of Counseling & Related Educational ... Center for Counseling & Family Studies , is under the ... new School of Behavioral Sciences. Prior to the formation of ...
(Date:1/22/2015)... January 22, 2015 Gabe’s Chemo Duck Program is ... the first app ever created for kids with cancer. The Chemo ... and devices, is filled with enjoyable games to help children of ... The free app helps to keep kids entertained, educated and at ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many ... it on Facebook, Twitter, and Pinterest. The fans will have ... a lottery every week. , Moreover, the company has extended ... Angelweddingdress homepage for more information. , Angelweddingdress ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Juvent Sports ... at the 2015 PGA Merchandise Show to bestow a ... incredible female amateur golfer, Arlene McKitrick. The award commemorated ... amateur golf tournament win. She won her first amateur ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of Cruz ... has treated just about every type of injury that can result ... those same twenty-plus years, the team at Doctors on Liens ... best possible doctor. With the combined breadth of experience ...
Breaking Medicine News(10 mins):Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2
... HUNTERSVILLE, N.C., Aug. 3 Are microbes ... you fill their book bags with school supplies that feature built-in ... that can cause stains, odors and product deterioration. , , ... grow. Microban antimicrobial technology is now infused into a growing number ...
... , , TEMPLE, Texas, ... Knight, MD, recently presented at a national conference in Washington, DC titled ... & White Healthcare was the only Texas health care system and one ... the forum. , , The event was ...
... , CRANBURY, N.J., Aug. 3 Innophos Holdings, Inc. (Nasdaq: ... today announced its financial results for the second quarter 2009. , , ... , Net sales for the second quarter 2009 ... $264.0 million for the same period in 2008. Selling price increases had ...
... , WASHINGTON, Aug. 3 American Life League ... organizations to condemn the Obama healthcare plan in the wake of ... http://www.newscom.com/cgi-bin/prnh/20081105/DC44231LOGO ) , , ... the Catholic Health Association are urging their members to support "healthcare ...
... An international ... may lead to new areas for drug development in melanoma - a cancer that is ... ... identified a new method for selectively killing metastatic melanoma cells, which may lead to new ...
... Kan., Aug. 3 Laboratory studies at Kansas State University and ... effort to control the pandemic H1N1 virus. , , ... of Veterinary Medicine and is a Kansas Bioscience Authority Eminent Scholar. ... characteristics of the pandemic H1N1 virus. , , ...
Cached Medicine News:Health News:Are Microbes Headed Back to School this Fall? 2Health News:Scott & White Leadership Invited to National Forum on High Quality, Low-Cost Health Care 2Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 2Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 3Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 4Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 5Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 6Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 7Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 8Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 9Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 10Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 11Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 12Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 13Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 14Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 15Health News:Despite Attacks, A.L.L. Calls on Catholic Organizations to Condemn 'Obamacare' 2Health News:Despite Attacks, A.L.L. Calls on Catholic Organizations to Condemn 'Obamacare' 3Health News:Researchers Identify New Method to Selectively Kill Metastatic Melanoma Cells 2Health News:Researchers Identify New Method to Selectively Kill Metastatic Melanoma Cells 3Health News:K-State Researcher, Collaborators Study Virulence of Pandemic H1N1 Virus; Work at K-State Would Protect Pig Industry If the Virus Jumps to Swine Populations 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: